Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Steffee, C. H.
Right arrow Articles by Wasilauskas, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steffee, C. H.
Right arrow Articles by Wasilauskas, B. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 40, 595-598, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

Clinical use of rifampicin during routine reporting of rifampicin susceptibilities: a lesson in selective reporting of antimicrobial susceptibility data

CH Steffee, RM Morrell and BL Wasilauskas
Department of Pathology, Bowman Gray School of Medicine, Winston-Salem, NC 27157, USA. steffee@bgsm.edu

Increased use of rifampicin for in-patients was noted after the laboratory began reporting rifampicin susceptibilities routinely for all Gram-positive bacterial isolates. The appropriateness of rifampicin use was evaluated by chart review for in-patients administered rifampicin during two time periods, before and during routine rifampicin susceptibility reporting, respectively. While rifampicin susceptibility was reported routinely, four patients were subjected to potentially harmful misuse of rifampicin. These findings reconfirm the necessity of interdepartmental consultation and extensive staff education whenever a modification of antimicrobial susceptibility profile reporting is contemplated. Furthermore, they underscore the role of the clinical microbiology laboratory in guiding antimicrobial therapy through limited reporting of susceptibility data.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
O. Cirioni, C. Silvestri, R. Ghiselli, F. Orlando, A. Riva, F. Mocchegiani, L. Chiodi, S. Castelletti, E. Gabrielli, V. Saba, et al.
Protective effects of the combination of {alpha}-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection
J. Antimicrob. Chemother., December 1, 2008; 62(6): 1332 - 1338.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.